On Thursday, the drug Tezspire, developed by Amgen and AstraZeneca, demonstrated effectiveness in treating an esophageal disease prevalent among approximately 470,000 patients in the United States. The success of Tezspire has raised speculations about its potential to compete with Dupixent, as reported by Investor's Business Daily.